A preliminary study of anticholinergic burden and relationship to a quality of life indicator, engagement in activities, in nursing home residents with dementia.
OBJECTIVE
(1) To describe the anticholinergic burden experienced by nursing home residents with dementia using the Anticholinergic Cognitive Burden (ACB) Scale; and (2) to determine the association of anticholinergic burden and engagement in activity.


METHODS
Cross-sectional, using baseline data from an ongoing clinical trial.


METHODS
Nine nursing homes in Pennsylvania.


METHODS
Eighty-seven nursing home residents with dementia


METHODS
The ACB Scale was used to classify the severity of each resident's prescribed drugs' anticholinergic activity on cognition. Engagement in activity was measured by direct observation using a standard instrument.


RESULTS
Across 775 observations, subjects were active approximately 54% of the time, doing nothing 24% of the time, and asleep over 21% of the time. Seventy-one (81.6%) subjects were prescribed at least one drug with anticholinergic properties and 32 (36.7%) were prescribed at least one drug with severe anticholinergic properties. On average, subjects had a total ACB score of 2.55 (+/- 1.9). Mental status (MMSE) and dependency (PGDRS) were associated with engagement, but use of anticholinergic drugs was not.


CONCLUSIONS
Nursing home residents are prescribed many drugs with anticholinergic properties. The ACB Scale has utility as a tool to alert practitioners to high anticholinergic burden, who can then use this information when choosing between equally efficacious medications. Further study using larger samples of persons with dementia in earlier stages of the disease, and use of intense measurement designs are needed to more clearly determine the association of ACB with quality of life indicators.
Kolanowski
Ann
A
School of Nursing, Pennsylvania State University, University Park, PA 16802, USA. amk20@psu.edu
Fick
Donna M
DM
Campbell
Judy
J
Litaker
Mark
M
Boustani
Malaz
M
D000368:Aged; D000369:Aged, 80 and over; D018680:Cholinergic Antagonists / Q000627:therapeutic use*; D003071:Cognition / Q000187:drug effects*; D003430:Cross-Sectional Studies; D003704:Dementia / Q000188:drug therapy; D004363:Drug Utilization; D005260:Female; D006707:Homes for the Aged; D006801:Humans; D008297:Male; D009735:Nursing Homes; D011788:Quality of Life
D018680:Cholinergic Antagonists